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Introduction
The G protein-coupled receptors (GPCRs) form a large family of membrane bound proteins which share a unique structural feature comprising 7 transmembrane alpha helices. These molecules act as receptors for a diverse range of extracellular signalling molecules including small molecules (amino acids, biogenic amines), lipids, small bioactive peptides and large polypeptides (1) . They have been successfully used as drug targets by the pharmaceutical industry for a number of years. Attention has focussed on a number of proteins which are known to be GPCRs through structural homology, but for which no ligand has been identified -so called orphan receptors. At the same time as the recent discovery of new GPCRs, there has been a renewed focus on discovering potential novel peptides which may act as endogenous ligands for these receptors.
Here, we describe the cloning of a novel human orphan receptor, a class I GPCR with sequence similarity to receptors for the neuropeptide galanin. This receptor was given the name AXOR12, in accordance with its position in a series of receptors identified in our organization. AXOR12 has a high degree of homology to the rat orphan receptor GPR54 (2) (81% amino acid identity) which suggests that these two receptors may be orthologs. In order to identify a ligand for AXOR12 we expressed this receptor in mammalian cells, and screened the transfected cells in a functional assay against a library rich in known and putative peptide transmitters. While there was no activity in response to galanin, we identified three peptides which acted as low potency agonists of AXOR12. These peptides were all derived from invertebrates and shared a Cterminal LRF-or LRW-amide motif.
During the preparation of this manuscript, a search of patent literature revealed the existence of additional, high potency agonists with sequence similarities to the surrogate agonists identified by guest on http://www.jbc.org/ Downloaded from 4 from the screen. These peptides were derived from a precursor known as KiSS-1. The KiSS-1 gene was originally identified as being upregulated in melanoma cells which have lost the potential to metastasize following microcell mediated transfer of human chromosome 6 (3).
Subsequent studies have shown that exogenous expression of KiSS-1 in other tumor cell lines also prevents metastasis (4) . The mechanism by which this occurs remains largely unknown, however KiSS-1 has structural features that suggest that it may be the precursor of a secreted peptide with an LRF-amide motif at the C-terminus. We synthesized the putative processed products of KiSS-1 and observed that they acted as high potency agonists of AXOR12.
In order to gain insight into the physiological role of this receptor, we used quantitative RT-PCR to localize the mRNA expression of AXOR12 and of KiSS-1 in a range of human tissues. We observed high levels of AXOR12 expression in the brain. Further RT-PCR analysis of brain expression revealed a distinctive pattern of mRNA localisation which was further explored by immunohistochemistry using an antibody raised to the extreme C-terminal tail of the receptor. 
Experimental Procedures

Receptor Cloning
The human AXOR12 gene was initially identified within a genomic clone (AC005379) as five coding exons interrupted by 4 introns. The full-length cDNA was obtained by a modification of a previously described cDNA capture method (5) . Briefly, 5µg of plasmid DNA from a human brain cDNA library was screened with a biotinylated oligonucleotide (5'-biotin with 18 atom spacer) corresponding to the 5' coding region (5'-GATGCGGACCGTGACCAACTTCTAC-3').
Two additional 40-mers ( 5'-GGAACTCGCTGGTCATCTACGTCATCTGCCGCCACAAGCC-
3'
and 5'-ATCGCCAACCTGGCGGCCACGGACGTGACCTTCCTCCTGTG-3'), corresponding to the immediate 5' and 3' regions of the biotinylated probe were also used as blocking oligos. Bacterial colonies from the second round of selection were screened by PCR using AXOR12 specific primers. Five positive clones were identified and the entire inserts were sequenced on both strands using an ABI sequencer. Two of the sequenced clones were identical to each other and to the full length AXOR12 cDNA predicted from the genomic DNA sequence.
Heterologous Receptor Expression and Functional Analysis in Mammalian Cells
The AXOR12 cDNA was subcloned into the mammalian expression vector pCDN (6) as described previously (7) . Transient transfections of HEK293 cells with AXOR12 alone or AXOR12 co-transfected with Gqi5 (a chimeric G protein α subunit consisting of G αq with the Cterminal 5 amino acids substituted with the corresponding amino acids from G αi2 , which facilitates GPCR signalling through phospholipase C) were prepared for functional studies. A Ca 2+ mobilization assay using the microtiter plate-based Ca 2+ mobilization fluorometric imaging plate reader (FLIPR) was performed as described previously (8) . HEK293 cells co-transfected 6 with AXOR12 and Gqi5 were screened against a large library of over 1500 known and putative GPCR agonists, including all available mammalian neuropeptides, as described previously (9) .
Peptides in this library were tested at a final concentration of > 100 nM and other potential small molecule agonists at > 1 µM.
To obtain mammalian cells stably expressing AXOR12, the cDNA was subcloned into the vector pCD (a derivative of pCDN lacking the gene for neomycin resistance) and co-transfected with pCDN Gqi5 (10) 
. Levels of mRNA measured were calculated as copies of mRNA detected per ng of reverse transcribed polyA+ RNA.
Receptor protein localization studies
A unique synthetic peptide (CVLGEDNAPL) located at the extreme C-terminus of the human AXOR12 receptor sequence, corresponding to amino acids 389-398, was synthesised (Bio Synthesis Incorporated). Polyclonal antibodies were produced as described in detail elsewhere (13) . In brief, New Zealand white rabbits were injected with peptide-PPD conjugate and were boosted at regular intervals. Crude bleeds were tested for antibody titre using a standard ELISA protocol. AXOR12 antiserum was purified from crude rabbit serum by immunoaffinity chromatography on peptide-coupled Sulfolink™ gel (Pierce Chemical Company). Western blotting was carried out essentially as described elsewhere (13) . In brief, membranes were 
Results
As part of an ongoing effort to identify ligands for novel human orphan GPCRs, we cloned a novel GPCR, originally identified within a genomic clone, using a cDNA capture method. As shown in Fig 1, this receptor, AXOR12 , encodes a 398-amino acid protein. TMHMM, a program that uses a hidden Markov model for predicting transmembrane helices (15) , predicted that the protein contained 7 hydrophobic putative transmembrane domains. AXOR12 has sequence homology with class I members of the GPCR superfamily, exhibiting highest sequence homology (81% amino acid identity) to GPR54, a rat receptor previously characterized as a galanin receptor-like orphan (2). The human GPCRs to which AXOR12 has closest homology are members of the galanin receptor family, sharing 28%, 30% and 30% amino acid identity with human GalR1, GalR2 and GalR3, respectively.
We adopted a "reverse pharmacological" strategy (16) to identify agonists for AXOR12. Thus, HEK293 cells co-transfected with AXOR12 and Gqi5 were challenged with a large library of more than 1500 putative ligands, and responses measured in a microtiter plate-based (FLIPR) calcium mobilization assay. We observed that specific responses were elicited by two neuropeptides originally isolated from the sea anemone Anthopleura elegantissima; antho-RWamide I (17) and antho-RW-amide II (18) and a neuropeptide from the lobster; peptide F1 (19) (sequences shown in Table 1 ). Further experiments demonstrated that these responses were not dependent upon co-transfection of the recombinant chimeric G protein and were concentration dependent with EC 50 values in the low micromolar range (Fig 2) . For further studies, CHO AXOR12:Gqi5 cells were utilized. The CHO parental cells did not respond to the peptides studied here, but the transfected cell line responded to the three surrogate agonists (Fig 4 and Table 1 ). Galanin and galanin-like peptide, when tested at concentrations up to 1 µM did not (Table 1) revealed that these peptides were substantially more potent than the non-mammalian LRF-or LRW-amide peptides tested (Fig 4, Table 1 ). Of the four truncated KiSS-1 sequences, the decapeptide 112- to the 54 amino acid peptide corresponding to the entire putative secreted segment of KiSS-1, tested in separate experiments, resulted in a further reduction in potency (Table 1) . Peptides corresponding to the N-terminus of the putative secreted segment and also to putatively non-12 secreted segments of KiSS-1 were inactive (pEC 50 <5) (Table 1) . NPFF, NPAF and the RFamide like peptides active at the type I neuropeptide FF receptor, NPFFR1 (21) were also tested and all failed to generate a response (pEC 50 <5, data not shown).
The calcium mobilization response seen following activation of AXOR12 when transiently transfected without additional G protein α-subunits into HEK293 cells (Fig 2) suggests that this receptor is coupled to G proteins of the G q/11 subfamily. In agreement with this hypothesis, KiSS-1 (112-121) caused identical calcium mobilization in both control and pertussis toxin- To characterize the expression pattern of both the receptor AXOR12 and its putative ligand KiSS-1 we carried out quantitative RT-PCR analysis on a broad range of human tissues.
AXOR12 was widely expressed in human tissues including the placenta, brain and pituitary at high levels ( Fig. 5 ) with lower levels detected in lymphocytes, pancreas and adipose tissue.
Within the human CNS, AXOR12 mRNA was widespread in its expression, including the amygdala, nucleus accumbens, hippocampus and cingulate gyrus (Fig. 6 ). KiSS-1 mRNA was detected predominantly in the placenta (Fig 5) but was also widespread throughout the CNS, although at much lower levels (Fig. 6 ).
To gain a greater understanding of the specific cellular localisation and level of protein expression of AXOR12, we generated an antiserum directed against a C-terminal peptide from (Fig. 7B) . These immunoreactive bands were competed out by the immunising peptide (data not shown). In both cases, the 75 kDa protein detected agrees with the predicted size of the native AXOR12 receptor together with a probable degree of glycosylation at extracellular consensus sites (see Fig. 1 ).
The AXOR12 receptor-specific antiserum was used to localise receptor immunoreactivity in CHO AXOR12:Gqi5 cells. Expression of the receptor was detected both at the membrane and within the cells (Fig 7C) , although only a subset of the cells were immunoreactive for AXOR12 (Fig 7C, D) .
Immunohistochemical analysis of human brain sections revealed prominent neuronal expression in the regions sampled including the cerebral cortex, thalamus, pons-medulla and cerebellum. In the cerebral cortex AXOR12 specific staining was present on a large number of pyramidal neurones of layers III and V and VI (Fig 8A) . However in the basal ganglia (caudate nucleus, putamen, globus pallidus and substantia nigra) staining was primarily localised to AXOR12
immunoreactive fibres and processes. In the cerebellum AXOR12 was strikingly localised to the surface of the Purkinje cells and their apical dendrites (Fig 8B) and to a lesser extent the cells of the deep cerebellar nuclei. In the pons-medulla AXOR12 immunoreactivity was widespread in a number of nuclei including the raphe nuclei, inferior olive and hypoglossal nuclei (Fig 8C) .
AXOR12 staining was abolished when the antibody was preabsorbed with 10 µM immunogenic peptide (Fig 8D, E) or when the primary antibody was omitted (data not shown).
Discussion.
In this paper we describe the cloning of a potential human ortholog of the rat G protein-coupled receptor GPR54, which we term AXOR12. A number of peptides, possessing an LRW-amide or an LRF-amide motif at the C-terminus are identified as surrogate ligands of AXOR12.
The first RF-amide peptide to be described was FMRFamide, a cardioexcitatory neuropeptide isolated from the bivalve mollusk Macrocallista nimbosa (22) . Some orphan receptors have been shown to be activated by naturally occurring peptides from lower organisms which have structural similarity to the cognate neuropeptide ligand for these receptors (27) . For this reason we screened AXOR12 against a library with a wide diversity of mammalian and non-mammalian peptides. On the basis of our initial screen we reasoned that the natural ligand for AXOR12 was likely to contain a LRF-or LRW-amide motif at its C-terminus.
KiSS-1, a putative human neuropeptide with an LRF-amide motif identified from the patent literature was therefore a candidate cognate ligand for this receptor.
Structurally, KiSS-1 bears all of the hallmarks of a secreted neuropeptide, with a putative signal sequence and several sites amenable to cleavage including an amidation/cleavage site that would result in a number of amidated peptide fragments of various lengths. We synthesised a number of putative N-terminally truncated products of this peptide and tested them against AXOR12. Expression of KiSS-1 in normal tissues was initially detected only in placenta (3). Our own observations have shown that, while KiSS-1 mRNA is extremely abundant in the placenta, low levels of message are also found in the brain, and more specifically in the hypothalamus and basal ganglia. This distribution pattern is consistent with the mRNA localisation of AXOR12, which is also in placenta, several CNS regions and pituitary. Our data on AXOR12 localisation broadly correspond to the published data for the putative rat ortholog GPR54 (2).
Immunohistochemical data indicate that expression of the receptor occurs specifically on a number of neuronal cell types in the human CNS regions that were examined. Indeed, neuronal localisation of AXOR12 in many regions of the cerebral cortex, cerebellum and medulla fits well The high levels of expression of both KiSS-1 and AXOR12 in placenta are also noteworthy in this respect. The placenta is also an invasive tissue, and there are similarities in the behavior of invading cancer cells and that of invading placenta cells (34) . It is possible that KiSS-1 and AXOR12 may form part of a mechanism that is common to both of these processes.
In conclusion, AXOR12 constitutes a new human G protein-coupled receptor that has now been paired with its neuropeptide ligand, KiSS-1. Although there is still much to be discovered about both the receptor and its ligand, the biological evidence so far suggests that they may have important physiological roles both in the CNS and in tumor biology. As such, they represent an intriguing target for novel therapies in the fields of both neurology and oncology. 
